PAN-KRAS PDO Screen

EXPERT ANALYSIS

Multi-Selective RAS Inhibition: Clinical Validation and Preclinical Implications

"The Phase 3 RASolute 302 trial has established clinical proof of concept for multi-selective RAS inhibition. Daraxonrasib, an oral RAS(ON) multi-selective tri-complex inhibitor of the active GTP-bound state of mutant and wild-type RAS, nearly doubled median overall survival relative to standard-of-care chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma (13.2 versus 6.7 months), with concurrent improvement in progression-free survival. The trial enrolled 500 patients across 59 sites and included tumors carrying a broad range of RAS variants as well as tumors without an identified RAS mutation.

Two features of this result carry direct preclinical consequence. First, the agent addresses G12, G13, and Q61 variants as a class rather than a single allele, and survival benefit was observed irrespective of RAS mutation status. Second, the mechanism is state-dependent rather than pocket-dependent, distinguishing it from the switch-II pocket chemistry underlying approved G12C inhibitors.

HOW CAN WE HELP

For programs pursuing pan-KRAS, pan-RAS, or RAS(ON) mechanisms, the preclinical requirement is consequently breadth: demonstration of activity across the full allele spectrum, in multiple tumor indications, under standardized assay conditions permitting cross-model comparison. This is the design specification of our preset PAN-KRAS(ON) PDO Screen — a recurrent, high-throughput platform of 24 PDOs spanning clinically relevant KRAS mutations across colorectal, pancreatic, and lung cancer, generating comparative efficacy data across indications from a single enrollment."

Yasmine Abouleila, PhD
Global Strategic Scientific BD Manager, HUB Organoids

enroll in the PAN-KRAS(ON) PDO Screen